CHEMI PHARM GROUP - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 347,335 | 388,929 | 920,238 | 625,708 | 606,658 | 598,399 | 739,711 | 715,504 |
| Profit before tax | - | - | - | 134,490 | 27,732 | 52,801 | 30,670 | - |
| Net profit | 21,551 | 52,630 | 218,968 | 114,019 | 19,728 | 44,195 | 21,311 | 11,343 |
| Equity | 145,917 | 114,251 | 254,453 | 368,414 | 311,671 | 300,441 | 255,936 | 214,929 |
| Liabilities | 60,950 | 58,675 | 163,170 | 103,468 | 26,284 | 39,937 | 29,860 | 39,485 |
| Non-current assets | 8,552 | 7,745 | 4,336 | 31,082 | 30,403 | 24,216 | 20,103 | 17,885 |
| Current assets | 195,351 | 163,948 | 413,287 | 440,490 | 307,552 | 316,162 | 265,693 | 236,529 |
| Total assets | 203,903 | 171,693 | 417,623 | 471,572 | 337,955 | 340,378 | 285,796 | 254,414 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 89,600 | 100,752 | 119,139 |
| Social insurance contributions | - | - | - | - | - | 12,129 | 15,376 | 19,893 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +16.2% | +12.0% | +136.6% | -32.0% | -3.0% | -1.4% | +23.6% | -3.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 10.6% | 30.7% | 52.4% | 24.2% | 5.8% | 13.0% | 7.5% | 4.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 14.8% | 46.1% | 86.1% | 30.9% | 6.3% | 14.7% | 8.3% | 5.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.2% | 13.5% | 23.8% | 18.2% | 3.3% | 7.4% | 2.9% | 1.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | 21.5% | 4.6% | 8.8% | 4.1% | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.5 | 0.6 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 69,467 | 77,786 | 181,032 | 112,068 | 101,110 | 99,733 | 123,285 | 119,251 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
CHEMI PHARM GROUP - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-23 | 2026-07-26 | 1.71 |
| 2026-04-20 | 2026-04-21 | 1820.87 |
| 2022-09-16 | 2022-09-19 | 99.27 |
CHEMI PHARM GROUP - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-10 | 2025-01-10 | 12045.61 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
CHEMI PHARM GROUP, UAB (code 111694687) is a Private Limited Liability Company engaged in wholesale of other chemical products. In 2025, revenue was €715.5K, down 3.3% year on year, while net profit decreased to €11.3K from €21.3K in 2024 and €44.2K in 2023. The profit margin narrowed to 1.6% in 2025, compared with 2.9% in 2024 and 7.4% in 2023, showing a clear squeeze in profitability over the three-year period. Revenue nevertheless remained above the 2023 level, reflecting 19.6% growth over two years. At the end of 2025, total assets stood at €254.4K, with equity of €214.9K and liabilities of €39.5K. The equity ratio was 84.5% and debt-to-equity was 0.18, indicating a conservative balance sheet structure. Return on equity was 5.3% and return on assets 4.5%. Asset turnover reached 2.81x, suggesting efficient use of assets in generating sales. Revenue per employee was €119.3K and profit per employee €1.9K, pointing to moderate productivity but limited earnings conversion in 2025.